Surgical management of ulcerative colitis in the era of biologicals

Inflammatory Bowel Diseases

Volumn 21, Issue 1, 2015, Pages 208-220

  Devaraj, Bikash ^a   Kaiser, Andreas M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Biological treatment; Colectomy; Inflammatory bowel disease; Proctocolectomy; Salvage treatment; Steroid dependence; Steroid refractoriness; Ulcerative colitis

Indexed keywords

STEROID;

ANASTOMOSIS LEAKAGE; CANCER SURGERY; CHRONIC DISEASE; COCHRANE LIBRARY; COLON RESECTION; CONTINENT ILEOSTOMY; COST BENEFIT ANALYSIS; DISEASE COURSE; DISEASE ELIMINATION; HUMAN; ILEITIS; ILEOANAL ANASTOMOSIS; ILEORECTAL ANASTOMOSIS; ILEOSTOMY; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MEDLINE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; PROCTOCOLECTOMY; REVIEW; SURGEON; TREATMENT OUTCOME; ULCERATIVE COLITIS; WOUND INFECTION; COLITIS, ULCERATIVE; DISEASE MANAGEMENT; DRUG RESISTANCE; SALVAGE THERAPY;

COLITIS, ULCERATIVE; DISEASE MANAGEMENT; DRUG RESISTANCE; HUMANS; SALVAGE THERAPY; STEROIDS;

EID: 84925725964     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000178     Document Type: Review

References (127)

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361:2066-2078.
2. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996;39:690-697.
3. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-1517.
4. Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28:255-281.
5. Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012; 380:1606-1619.
6. Norgard BM, Nielsen J, Fonager K, et al. The incidence of ulcerative colitis (1995-2011) and Crohn's disease (1995-2012)-based on nationwide Danish registry data. J Crohns Colitis. [published online ahead of print March 24, 2014]. doi: 10.1016/j.crohns.2014.03.006.
7. Lashner BA. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 1995;24:467-474.
8. Guslandi M. Nicotine treatment for ulcerative colitis. Br J Clin Pharmacol. 1999;48:481-484.
9. Nikfar S, Ehteshami-Ashar S, Rahimi R, et al. Systematic review and meta-analysis of the efficacy and tolerability of nicotine preparations in active ulcerative colitis. Clin Ther. 2010;32:2304-2315.
10. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753.
11. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5A-36A.
12. Arrossi AV, Kariv Y, Bronner MP, et al. Backwash ileitis does not affect pouch outcome in patients with ulcerative colitis with restorative proctocolectomy. Clin Gastroenterol Hepatol. 2011;9:981-988.
13. Abdelrazeq AS, Kandiyil N, Botterill ID, et al. Predictors for acute and chronic pouchitis following restorative proctocolectomy for ulcerative colitis. Colorectal Dis. 2008;10:805-813.
14. Schmidt CM, Lazenby AJ, Hendrickson RJ, et al. Preoperative terminal ileal and colonic resection histopathology predicts risk of pouchitis in patients after ileoanal pull-through procedure. Ann Surg. 1998;227: 654-662; discussion 663-665.
15. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci. 1993;38:1137-1146.
16. Bernstein CN, Ng SC, Lakatos PL, et al. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis. 2013;19:2001-2010.
17. Fazio VW, Kiran RP, Remzi FH, et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg. 2013; 257:679-685.
18. Heikens JT, de Vries J, van Laarhoven CJ. Quality of life, health-related quality of life and health status in patients having restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: a systematic review. Colorectal Dis. 2012;14:536-544.
19. Koltun WA. Role of medical rescue therapy in the management of acute severe ulcerative colitis: the surgical perspective. Expert Rev Gastroenterol Hepatol. 2009;3:325-327.
20. Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014;160:704-711.
21. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369:699-710.
22. Buskens CJ, Sahami S, Tanis PJ, et al. The potential benefits and disadvantages of laparoscopic surgery for ulcerative colitis: a review of current evidence. Best Pract Res Clin Gastroenterol. 2014;28:19-27.
23. Heikens JT, de Vries J, Goos MRE, et al. Quality of life and health status before and after ileal pouch-anal anastomosis for ulcerative colitis. Br J Surg. 2012;99:263-269.
24. Hahnloser D, Pemberton JH, Wolff BG, et al. The effect of ageing on function and quality of life in ileal pouch patients: a single cohort experience of 409 patients with chronic ulcerative colitis. Ann Surg. 2004; 240:615-621; discussion 621-623.
25. Yang Z, Wu Q, Wang F, et al. Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment Pharmacol Ther. 2012;36:922-928.
26. Shen B. Impact of preoperative infliximab use on postoperative infectious complications in ulcerative colitis: the price we have to pay? Inflamm Bowel Dis. 2008;14:1019-1021.
27. Mor IJ, Vogel JD, da Luz Moreira A, et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum. 2008;51:1202-1207; discussion 1207-1210.
28. Ross H, Steele SR, Varma M, et al. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum. 2014;57:5-22.
29. Seicean A, Moldovan-Pop A, Seicean R. Ulcerative colitis worsened after Clostridium difficile infection: efficacy of infliximab. World J Gastroenterol. 2014;20:5135-5140.
30. Matsumoto S, Yoshida Y. What are the factors that affect hospitalization and surgery for aggravation of ulcerative colitis? Eur J Gastroenterol Hepatol. 2014;26:282-287.
31. Kopylov U, Eliakim-Raz N, Szilagy A, et al. Antiviral therapy in cytomegalovirus-positive ulcerative colitis: a systematic review and meta-analysis. World J Gastroenterol. 2014;20:2695-2703.
32. Ayre K, Warren BF, Jeffery K, et al. The role of CMV in steroid-resistant ulcerative colitis: a systematic review. J Crohns Colitis. 2009;3:141-148.
33. Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013;7:1-33.
34. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965-990.
35. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991-1030.
36. De Vos M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013;19:2111-2117.
37. Yoon JY, Park SJ, Hong SP, et al. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci. 2014;59:829-837.
38. Sehgal R, Koltun WA. Scoring systems in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010;4:513-521.
39. Bewtra M, Brensinger CM, Tomov VT, et al. An optimized patientreported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index. Inflamm Bowel Dis. 2014;20:1070-1078.
40. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
41. Bouguen G, Levesque BG, Pola S, et al. Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2014;20:231-239.
42. Deepak P, Bruining DH. Radiographical evaluation of ulcerative colitis. Gastroenterol Rep (Oxf). 2014;2:169-177.
43. Parbo P, Stribolt K, Rittig CS, et al. Active ulcerative colitis diagnosed by (18)F-FDG PET/CT in an anti-TNF alpha treated patient with no visible luminal lesions on colonoscopy. Int J Colorectal Dis. 2014;29:643-644.
44. Ventham NT, Kennedy NA, Duffy A, et al. Comparison of mortality following hospitalisation for ulcerative colitis in Scotland between 1998-2000 and 2007-2009. Aliment Pharmacol Ther. 2014;39:1387-1397.
45. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228-1233.
46. Castano-Milla C, Chaparro M, Gisbert JP. Systematic review with metaanalysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther. 2014;39:645-659.
47. Bitton A, Buie D, Enns R, et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107:179-194; author reply 195.
48. Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology. 2011;140:1827 e2-1837 e2.
49. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol. 2005;17:79-84.
50. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
51. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006:CD005112.
52. Feagan BG, MacDonald JK. Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:1785-1794.
53. Timmer A, McDonald JW, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;9:CD000478.
54. Danese S, Siegel CA, Peyrin-Biroulet L. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2014;39:1095-1103.
55. Sachar DB. Maintenance therapy in ulcerative colitis and Crohn's disease. J Clin Gastroenterol. 1995;20:117-122.
56. Kaur M, Targan SR. Ulcerative colitis: steroid-refractory ulcerative colitisciclosporin or infliximab? Nat Rev Gastroenterol Hepatol. 2013;10:8-9.
57. Garcia-Lopez S, Gomollon-Garcia F, Perez-Gisbert J. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol. 2005;28:607-614.
58. Travis S, Satsangi J, Lemann M. Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut. 2011;60:3-9.
59. Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther. 2004;19:1079-1087.
60. Reinisch W, Sandborn WJ, Rutgeerts P, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18:201-211.
61. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353: 1912-1925.
62. Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med. 2009;361: 1067-1074.
63. Williet N, Pillot C, Oussalah A, et al. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflamm Bowel Dis. 2012;18:1641-1646.
64. Aratari A, Papi C, Clemente V, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis. 2008;40:821-826.
65. Ferrante M, Declerck S, De Hertogh G, et al. Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Inflamm Bowel Dis. 2008;14:20-28.
66. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250-1260; quiz 1520.
67. Teisner AS, Ainsworth MA, Brynskov J. Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: a Danish single center experience. Scand J Gastroenterol. 2010;45:1457-1463.
68. Halpin SJ, Hamlin PJ, Greer DP, et al. Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience. World J Gastroenterol. 2013;19:1091-1097.
69. Moore SE, McGrail KM, Peterson S, et al. Infliximab in ulcerative colitis: the impact of preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia, Canada. Dis Colon Rectum. 2014;57:83-90.
70. Monterubbianesi R, Aratari A, Armuzzi A, et al. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. J Crohns Colitis. 2014;8:852-858.
71. Lawlor G, Moss AC. Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update. Clin Exp Gastroenterol. 2009;2:149-161.
72. Cannom RR, Kaiser AM, Ault GT, et al. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates? Am Surg. 2009;75:976-980.
73. Sanderson JD, Parkes GC. Timing of surgery for inflammatory bowel disease. BMJ. 2007;335:1006.
74. Roberts SE, Williams JG, Yeates D, et al. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies. BMJ. 2007;335:1033.
75. Ellis MC, Diggs BS, Vetto JT, et al. Trends in the surgical treatment of ulcerative colitis over time: increased mortality and centralization of care. World J Surg. 2011;35:671-676.
76. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936.
77. Kaiser AM, Beart RW Jr. Surgical management of ulcerative colitis. Swiss Med Wkly. 2001;131:323-337.
78. Coakley BA, Telem D, Nguyen S, et al. Prolonged preoperative hospitalization correlates with worse outcomes after colectomy for acute fulminant ulcerative colitis. Surgery. 2013;153:242-248.
79. Mayer R, Wong WD, Rothenberger DA, et al. Colorectal cancer in inflammatory bowel disease: a continuing problem. Dis Colon Rectum. 1999;42:343-347.
80. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-523; quiz 524.
81. Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. Gut. 1992;33:938-941.
82. Lashner BA, Turner BC, Bostwick DG, et al. Dysplasia and cancer complicating strictures in ulcerative colitis. Dig Dis Sci. 1990;35: 349-352.
83. Chambers WM, Mc CMNJ. Should ileal pouch-anal anastomosis include mucosectomy? Colorectal Dis. 2007;9:384-392.
84. Selvaggi F, Pellino G, Canonico S, et al. Systematic review of cuff and pouch cancer in patients with ileal pelvic pouch for ulcerative colitis. Inflamm Bowel Dis. 2014;20:1296-1308.
85. Kaiser AM. McGraw-Hill Manual Colorectal Surgery. 1st ed. New York, NY: McGraw-Hill Publishers; 2009.
86. Taylor BA, Wolff BG, Dozois RR, et al. Ileal pouch-anal anastomosis for chronic ulcerative colitis and familial polyposis coli complicated by adenocarcinoma. Dis Colon Rectum. 1988;31:358-362.
87. Ziv Y, Fazio VW, Sirimarco MT, et al. Incidence, risk factors, and treatment of dysplasia in the anal transitional zone after ileal pouchanal anastomosis. Dis Colon Rectum. 1994;37:1281-1285.
88. Ikeuchi H, Uchino M, Matsuoka H, et al. Surgery for ulcerative colitis in 1,000 patients. Int J Colorectal Dis. 2010;25:959-965.
89. Andersson P, Norblad R, Soderholm JD, et al. Ileorectal anastomosis in comparison with ileal pouch anal anastomosis in reconstructive surgery for ulcerative colitis-a single institution experience. J Crohns Colitis. 2013;8:582-589.
90. Kohler LW, Pemberton JH, Zinsmeister AR, et al. Quality of life after proctocolectomy. A comparison of Brooke ileostomy, Kock pouch, and ileal pouch-anal anastomosis [see comments]. Gastroenterology. 1991; 101:679-684.
91. Carlstedt A, Fasth S, Hulten L, et al. Long-term ileostomy complications in patients with ulcerative colitis and Crohn's disease. Int J Colorectal Dis. 1987;2:22-25.
92. Kock NG. Intra-abdominal "reservoir" in patients with permanent ileostomy. Preliminary observations on a procedure resulting in fecal "continence" in five ileostomy patients. Arch Surg. 1969;99:223-231.
93. Nessar G, Fazio VW, Tekkis P, et al. Long-term outcome and quality of life after continent ileostomy. Dis Colon Rectum. 2006;49:336-344.
94. Ojerskog B, Kock NG, Nilsson LO, et al. Long-term follow-up of patients with continent ileostomies. Dis Colon Rectum. 1990;33:184-189.
95. Dozois RR, Kelly KA, Ilstrup D, et al. Factors affecting revision rate after continent ileostomy. Arch Surg. 1981;116:610-613.
96. Kaiser AM. T-pouch: results of the first 10 years with a nonintussuscepting continent ileostomy. Dis Colon Rectum. 2012;55:155-162.
97. Barnett WO. Modified techniques for improving the continent ileostomy. Am Surg. 1984;50:66-69.
98. Fazio VW, Tjandra JJ. Technique for nipple valve fixation to prevent valve slippage in continent ileostomy. Dis Colon Rectum. 1992;35: 1177-1179.
99. Kaiser AM, Stein JP, Beart RW Jr. T-pouch: a new valve design for a continent ileostomy. Dis Colon Rectum. 2002;45:411-415.
100. Gemlo BT, Wong WD, Rothenberger DA, et al. Ileal pouch-anal anastomosis. Patterns of failure. Arch Surg. 1992;127:784-786; discussion 787.
101. Bauer JJ, Gorfine SR, Gelernt IM, et al. Restorative proctocolectomy in patients older than fifty years. Dis Colon Rectum. 1997;40:562-565.
102. MacRae HM, McLeod RS, Cohen Z, et al. Risk factors for pelvic pouch failure. Dis Colon Rectum. 1997;40:257-262.
103. Meagher AP, Farouk R, Dozois RR, et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998;85:800-803.
104. Breen EM, Schoetz DJ Jr, Marcello PW, et al. Functional results after perineal complications of ileal pouch-anal anastomosis. Dis Colon Rectum. 1998;41:691-695.
105. Neilly P, Neill ME, Hill GL. Restorative proctocolectomy with ileal pouch-anal anastomosis in 203 patients: the Auckland experience. Austr N Z J Surg. 1999;69:22-27.
106. Dayton MT, Larsen KR, Christiansen DD. Similar functional results and complications after ileal pouch-anal anastomosis in patients with indeterminate vs ulcerative colitis. Arch Surg. 2002;137:690-694; discussion 694-695.
107. Lepisto A, Luukkonen P, Jarvinen HJ. Cumulative failure rate of ileal pouch-anal anastomosis and quality of life after failure. Dis Colon Rectum. 2002;45:1289-1294.
108. Tulchinsky H, Hawley PR, Nicholls J. Long-term failure after restorative proctocolectomy for ulcerative colitis. Ann Surg. 2003;238:229-234.
109. Michelassi F, Lee J, Rubin M, et al. Long-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational study. Ann Surg. 2003;238:433-441; discussion 442-445.
110. Hahnloser D, Pemberton JH, Wolff BG, et al. Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Br J Surg. 2007;94:333-340.
111. Rickard MJ, Young CJ, Bissett IP, et al; Research Committee of the Colorectal Surgical Society of Australasia. Ileal pouch-anal anastomosis: the Australasian experience. Colorectal Dis. 2007;9:139-145.
112. Murrell ZA, Melmed GY, Ippoliti A, et al. A prospective evaluation of the long-term outcome of ileal pouch-anal anastomosis in patients with inflammatory bowel disease-unclassified and indeterminate colitis. Dis Colon Rectum. 2009;52:872-878.
113. Leowardi C, Hinz U, Tariverdian M, et al. Long-term outcome 10 years or more after restorative proctocolectomy and ileal pouch-anal anastomosis in patients with ulcerative colitis. Langenbecks Arch Surg. 2010; 395:49-56.
114. Heikens JT, de Vries J, de Jong DJ, et al. Evaluation of long-term function, complications, quality of life and health status after restorative proctocolectomy with ileo neo rectal and with ileal pouch anal anastomosis for ulcerative colitis. Colorectal Dis. 2013;15:e323-e329.
115. Lofland JH, Mallow P, Rizzo J. Cost-per-remission analysis of infliximab compared to adalimumab among adults with moderate-to-severe ulcerative colitis. J Med Econ. 2013;16:461-467.
116. Holubar SD, Long KH, Loftus EV Jr, et al. Long-term direct costs before and after proctocolectomy for ulcerative colitis: a population-based study in Olmsted County, Minnesota. Dis Colon Rectum. 2009;52:1815-1823.
117. Punekar YS, Hawkins N. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis. Eur J Health Econ. 2010;11:67-76.
118. Park KT, Tsai R, Perez F, et al. Cost-effectiveness of early colectomy with ileal pouch-anal anastamosis versus standard medical therapy in severe ulcerative colitis. Ann Surg. 2012;256:117-124.
119. Patel SS, Patel MS, Goldfarb M, et al. Elective versus emergency surgery for ulcerative colitis: a National Surgical Quality Improvement Program analysis. Am J Surg. 2013;205:333-337; discussion 337-338.
120. Lake JP, Firoozmand E, Kang JC, et al. Effect of high-dose steroids on anastomotic complications after proctocolectomy with ileal pouch-anal anastomosis. J Gastrointest Surg. 2004;8:547-551.
121. Biondi A, Zoccali M, Costa S, et al. Surgical treatment of ulcerative colitis in the biologic therapy era. World J Gastroenterol. 2012;18:1861-1870.
122. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007;204:956-962; discussion 962-963.
123. Schluender SJ, Ippoliti A, Dubinsky M, et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum. 2007;50:1747-1753.
124. Bordeianou L, Kunitake H, Shellito P, et al. Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgery. Int J Colorectal Dis. 2010;25:401-404.
125. Kunitake H, Hodin R, Shellito PC, et al. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg. 2008;12:1730-1736; discussion 1736-1737.
126. Ferrante M, D'Hoore A, Vermeire S, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis. 2009;15:1062-1070.
127. Gainsbury ML, Chu DI, Howard LA, et al. Preoperative infliximab is not associated with an increased risk of short-term postoperative complications after restorative proctocolectomy and ileal pouch-anal anastomosis. J Gastrointest Surg. 2011;15:397-403.